For more than a century, Bristol Myers Squibb has evolved through scientific breakthroughs, acquisitions and the constant challenge of keeping its medicine portfolio relevant.
The modern company took shape in 1989 through the merger of Bristol-Myers and Squibb, bringing together pharmaceutical businesses whose histories stretch back to the 19th century. Today, BMS operates across oncology, hematology, immunology, cardiovascular medicine, neuroscience and cell therapy, with its future increasingly tied to a new generation of medicines.
That transition matters because pharmaceutical companies live on a different clock from most businesses: successful medicines eventually face competition, patent expiration and declining revenue. BMS is therefore not simply trying to grow. It is trying to replace today’s blockbusters before tomorrow’s revenue gap arrives.
Financial Highlights (FY2025)
Bristol Myers Squibb generated US$48.2 billion in revenue in 2025, broadly in line with the previous year. Beneath that stable headline, however, the company’s portfolio was changing significantly.
- Revenue (FY2025): US$48.2 billion
- GAAP Net Earnings: US$7.1 billion
- GAAP EPS: US$3.46
- Non-GAAP EPS: US$6.15
- Growth Portfolio Revenue: US$26.4 billion (+17%)
- Legacy Portfolio Revenue: US$21.8 billion (-15%)
- R&D Investment: ~US$10 billion
- Employees: ~34,000
- Market Cap: ~US$130 billion
The most important number may not be total revenue. It is the US$26.4 billion Growth Portfolio, which increased 17% and represented more than half of BMS’s 2025 revenue. The company describes this portfolio as a collection of medicines earlier in their lifecycles with longer growth runways.
That shift from legacy medicines toward newer products is the central story behind BMS’s current strategy.
The Numbers Reveal A Portfolio In Transition
BMS’s 2025 results show two businesses moving in opposite directions.
Its Growth Portfolio generated US$26.4 billion, driven by medicines including Opdivo, Reblozyl, Breyanzi, Opdualag and Camzyos.
At the same time, the Legacy Portfolio generated US$21.8 billion, down 15% as generic competition continued affecting several mature medicines. Eliquis remained exceptionally large, generating US$14.4 billion in 2025, while Opdivo generated approximately US$10.0 billion.
That creates a strategic equation familiar across the pharmaceutical industry:
Can new medicines grow faster than older medicines decline?
For BMS, the answer increasingly depends on its Growth Portfolio.
2026 Shows Whether The Strategy Is Working
The transition did not stop with 2025.
In the first quarter of 2026, BMS generated US$11.5 billion in revenue, up 3% year over year, while Growth Portfolio revenue increased 12% to US$6.2 billion. Management reaffirmed its full-year 2026 revenue guidance of approximately US$46.0 billion to US$47.5 billion.
The second quarter provided another important signal.
BMS reported approximately US$13.0 billion in quarterly revenue, with Growth Portfolio revenue reaching roughly US$7.6 billion, up about 15%. The strong quarter led the company to raise its full-year outlook.
The pattern is becoming clearer: the company’s newer medicines are increasingly carrying the growth burden while mature products face structural pressure.
Oncology Remains At The Center Of The Strategy
Cancer treatment remains one of BMS’s most important areas of expertise.
The company has built a large oncology ecosystem around immuno-oncology and targeted therapies, with products including:
- Opdivo
- Yervoy
- Opdualag
- Breyanzi
- Reblozyl
- Abecma
- Krazati
Opdivo remains particularly important. Its combination with Yervoy and other therapies has allowed BMS to expand its presence across multiple cancer indications, while newer formulations such as Opdivo Qvantig are designed to broaden how the therapy can be administered.
The strategy is therefore not simply about discovering a single replacement blockbuster. It is about building a portfolio capable of producing multiple durable revenue streams.
Cell Therapy Is Becoming A Bigger Part Of BMS
BMS has also built a significant position in cell therapy.
The acquisition of Celgene in 2019 dramatically expanded the company’s capabilities in hematology and oncology and brought important assets into the portfolio, including Breyanzi and Abecma.
Cell therapy is strategically different from traditional pharmaceutical products because it involves highly specialized manufacturing, logistics and clinical infrastructure.
That creates complexity, but it can also create competitive barriers.
BMS’s continued investment in this area reflects its broader effort to build capabilities that are difficult for competitors to replicate quickly.
The Real Challenge Is The Patent Clock
The pharmaceutical industry has a unique structural problem: success eventually creates its own expiration date.
A blockbuster medicine can generate billions of dollars annually, but once patents and other forms of market exclusivity weaken, generic or competing products can rapidly change the economics.
BMS has already experienced this with medicines such as Revlimid, Pomalyst and Sprycel.
That pressure explains why the company’s Growth Portfolio matters so much.
In 2025, Growth Portfolio revenue rose 17%, while Legacy Portfolio revenue declined 15%. The two numbers tell the story of BMS’s transformation more clearly than total revenue alone.
The company is effectively trying to build tomorrow’s pharmaceutical business while today’s largest products are still generating cash.
Innovation Is Not Limited To The Laboratory
BMS’s approach to innovation increasingly extends beyond internal research.
The company has used acquisitions, licensing agreements and strategic partnerships to add new science and accelerate its pipeline.
The 2019 Celgene acquisition remains the defining example. More recently, BMS expanded its portfolio through acquisitions including Karuna Therapeutics, Mirati Therapeutics and RayzeBio, while also pursuing collaborations such as its agreement with BioNTech around BNT327.
This strategy reflects an important reality of modern drug development.
Scientific innovation does not always happen inside a single company.
Large pharmaceutical companies increasingly act as platforms capable of identifying promising technologies, financing development and bringing successful therapies through global regulatory and commercial systems.
What BMS Is Building Next
BMS is concentrating investment on several areas that could define its next decade.
→ Oncology
→ Immuno-oncology
→ Cell therapy
→ Cardiovascular medicine
→ Neuroscience
→ Immunology
→ Precision medicine
The objective is not simply to produce more medicines.
It is to create a sufficiently diversified pipeline so that the company is not dependent on a small number of blockbuster products at any particular point in time.
That makes portfolio construction almost as important as individual drug discovery.
From Bristol-Myers And Squibb To A Modern Biopharma Company
The company’s history helps explain its current structure.
Bristol-Myers began in the 19th century, while Squibb also developed its pharmaceutical business during the same period. Their 1989 merger created the modern Bristol Myers Squibb, bringing together complementary capabilities and establishing a platform that could compete at global scale.
The company’s later history was shaped by acquisitions and scientific expansion, particularly in oncology, hematology and immunology.
The Celgene transaction in 2019 was one of the most consequential moves, adding major oncology and hematology capabilities and reshaping the company’s future portfolio.
Today, BMS is once again undergoing a portfolio transition—this time driven less by corporate consolidation and more by the need to create the next generation of medicines.
Why Bristol Myers Squibb Matters
BMS illustrates one of the defining challenges of the pharmaceutical industry.
Scale can provide enormous advantages in research, clinical development, manufacturing and global commercialization.
But scale does not eliminate the patent cycle.
A pharmaceutical company can generate tens of billions of dollars in annual revenue and still need to continuously replace products that are approaching maturity.
That makes sustainable pharmaceutical leadership a race between innovation and erosion.
BMS’s Growth Portfolio is its answer to that race.
Its success will ultimately depend on whether today’s newer medicines can become tomorrow’s foundation before the company’s older blockbusters decline too quickly.
Main Competitors
BMS competes across different therapeutic areas with some of the world’s largest pharmaceutical companies, including:
- Merck & Co.
- Johnson & Johnson
- Pfizer
- AbbVie
- AstraZeneca
The competitive landscape is increasingly shaped by oncology, immunology, cardiovascular medicine, neuroscience and advanced therapies.
But competition is not only about which company has the largest current portfolio.
It is increasingly about who can build the strongest pipeline for the next decade.
What Investors Should Watch
Several factors will determine how successfully BMS navigates its next pharmaceutical era.
Growth Portfolio performance
Newer medicines need to continue scaling fast enough to offset declines elsewhere.
Patent and generic pressure
Legacy products remain a major source of cash flow, but their contribution will continue changing as exclusivity expires.
Pipeline productivity
Clinical research must produce medicines capable of becoming meaningful commercial products.
Business development
Acquisitions and partnerships can accelerate innovation, but they also carry financial and integration risks.
R&D productivity
BMS invested approximately US$10 billion in research and development during 2025, making the productivity of that investment critical to its long-term growth.
The company’s future will ultimately be measured not by how many medicines it sells today, but by how effectively it creates the medicines that will matter tomorrow.
Market Snapshot
Company: Bristol Myers Squibb
Founded: 1989 as Bristol Myers Squibb
Headquarters: Princeton, New Jersey, United States
CEO: Christopher Boerner, Ph.D.
Industry: Biopharmaceuticals
Employees: ~34,000
Revenue (FY2025): US$48.2 billion
Growth Portfolio (FY2025): US$26.4 billion
R&D Investment (FY2025): ~US$10 billion
Market Cap: ~US$130 billion
Official Website: https://www.bms.com
